Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IKS04 Regimen in Advanced Solid Tumors
NCT07738939Phase 1Not yet recruiting
- Sponsor
- Iksuda Therapeutics
- Start
- Nov 2026
- Primary completion
- Dec 2028
- Countries
- 1
01
Overview
Phase 1, open-label trial of IKS04 in colorectal cancer (CRC), gastroesophageal junction cancer, gastric cancer (GC) and 5 more (5 arms), sponsored by Iksuda Therapeutics. Primary endpoints: Recommended Phase 2 Dose up to 24 months and Objective Response Rate up to 24 months. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
IKS04
03
Conditions
colorectal cancer (CRC)gastroesophageal junction cancergastric cancer (GC)pancreatic ductal adenocarcinoma (PDAC)biliary tract cancer (BTC)
Beyond the preview
Go deeper on NCT07738939.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07738939.